138 related articles for article (PubMed ID: 15160288)
1. Influence of telomerase activity on bone and soft tissue tumors.
Umehara N; Ozaki T; Sugihara S; Kunisada T; Morimoto Y; Kawai A; Nishida K; Yoshida A; Murakami T; Inoue H
J Cancer Res Clin Oncol; 2004 Jul; 130(7):411-6. PubMed ID: 15160288
[TBL] [Abstract][Full Text] [Related]
2. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness.
Sangiorgi L; Gobbi GA; Lucarelli E; Sartorio SM; Mordenti M; Ghedini I; Maini V; Scrimieri F; Reggiani M; Bertoja AZ; Benassi MS; Picci P
Int J Cancer; 2001 May; 95(3):156-61. PubMed ID: 11307148
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity.
Yan P; Coindre JM; Benhattar J; Bosman FT; Guillou L
Cancer Res; 1999 Jul; 59(13):3166-70. PubMed ID: 10397260
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of telomerase activity in soft tissue sarcomas.
Schneider-Stock R; Rys J; Jaeger V; Niezabitowski A; Kruczak A; Sokolowski A; Roessner A
Int J Oncol; 1999 Oct; 15(4):775-80. PubMed ID: 10493961
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors.
Tomoda R; Seto M; Tsumuki H; Iida K; Yamazaki T; Sonoda J; Matsumine A; Uchida A
Cancer; 2002 Sep; 95(5):1127-33. PubMed ID: 12209700
[TBL] [Abstract][Full Text] [Related]
6. Analysis of telomerase activity and telomere length in bone and soft tissue tumors.
Terasaki T; Kyo S; Takakura M; Maida Y; Tsuchiya H; Tomita K; Inoue M
Oncol Rep; 2004 Jun; 11(6):1307-11. PubMed ID: 15138570
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in soft-tissue and bone sarcomas.
Aogi K; Woodman A; Urquidi V; Mangham DC; Tarin D; Goodison S
Clin Cancer Res; 2000 Dec; 6(12):4776-81. PubMed ID: 11156234
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity in cell lines of pediatric soft tissue sarcomas.
Kleideiter E; Schwab M; Friedrich U; Koscielniak E; Schafer BW; Klotz U
Pediatr Res; 2003 Nov; 54(5):718-23. PubMed ID: 12904596
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity in skeletal sarcomas.
Aue G; Muralidhar B; Schwartz HS; Butler MG
Ann Surg Oncol; 1998; 5(7):627-34. PubMed ID: 9831112
[TBL] [Abstract][Full Text] [Related]
10. A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay.
Wen JM; Sun LB; Zhang M; Zheng MH
Mol Pathol; 1998 Apr; 51(2):110-2. PubMed ID: 9713596
[TBL] [Abstract][Full Text] [Related]
11. Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas.
Yoo J; Robinson RA
Arch Pathol Lab Med; 2000 Mar; 124(3):393-7. PubMed ID: 10705392
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity in small-cell and non-small-cell lung cancers.
Hiyama K; Hiyama E; Ishioka S; Yamakido M; Inai K; Gazdar AF; Piatyszek MA; Shay JW
J Natl Cancer Inst; 1995 Jun; 87(12):895-902. PubMed ID: 7666478
[TBL] [Abstract][Full Text] [Related]
13. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
[TBL] [Abstract][Full Text] [Related]
14. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity in benign bone tumors and tumor-like lesions.
Kido A; Schneider-Stock R; Hauptmann K; Roessner A
Pathol Res Pract; 1999; 195(11):753-7. PubMed ID: 10605695
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity in giant cell tumors of bone.
Matsuo T; Hiyama E; Sugita T; Shimose S; Kubo T; Mochizuki Y; Adachi N; Kojima K; Sharman P; Ochi M
Ann Surg Oncol; 2007 Oct; 14(10):2896-902. PubMed ID: 17653593
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.
Sasaki T; Tazawa H; Hasei J; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Uno F; Kagawa S; Morimoto Y; Urata Y; Ozaki T; Fujiwara T
Clin Cancer Res; 2011 Apr; 17(7):1828-38. PubMed ID: 21325287
[TBL] [Abstract][Full Text] [Related]
18. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients.
Sotillo-Piñeiro E; Sierrasesúmaga L; Patiñno-García A
Pediatr Res; 2004 Feb; 55(2):231-5. PubMed ID: 14630995
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours.
Patel RM; Folpe AL
Pathology; 2009; 41(6):527-32. PubMed ID: 19900100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
